BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

The U.S. FDA has missed a key deadline to decide whether to grant full approval to Novavax's (NASDAQ:NVAX) COVID-19 vaccine.

The delay in approval is a setback for Novavax, as the company had anticipated a positive outcome based on the FDA’s initial deadline. The FDA’s decision to require more data before proceeding with ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

US equity indexes regained lost ground to finish mostly higher on Monday, ahead of more tariffs that will likely be announced by the Trump administration this week. The Dow Jones Industrial Average ...

The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA's Center for Biologics Evaluation and Research, has sent reverberations throughout the ...

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...